Heterodimers between these two receptors have been shown to form the most potent mitogenic and transforming receptor complex in vitro [37], and coexpression of erbB2 and erbB3 have been shown to be significantly associated with decreased survival in breast cancer patients [38]. This evidence concerns the gene ERBB3 and breast carcinoma.